GLP-1 RAs Medications: a revolution in obesity management and cardiovascular disease prevention

Abstract

Obesity and cardiovascular diseases represent global public health challenges, requiring innovative therapeutic approaches. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a revolution in the treatment of these conditions. This study aims to analyze the benefits of GLP-1 RAs in obesity management and cardiovascular disease prevention. It is a literature review, in which scientific databases were consulted to gather evidence on the impact of these drugs. The results indicate that GLP-1 RAs promote significant weight loss, improve glycemic control, and exert cardioprotective effects, reducing adverse events such as myocardial infarction and stroke. Additionally, studies suggest potential neuroprotective and renal effects, expanding their therapeutic applications. However, adverse effects such as gastrointestinal symptoms and an increased risk of biliary disorders require continuous monitoring. It is concluded that GLP-1 RAs represent a promising approach for managing obesity and cardiovascular health, but further research is necessary to evaluate their long-term effects and optimize their clinical use.